Skip to main content

MESA LABORATORIES INC /CO/

For the period ended Dec 31, 2025. Filed Feb 3, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2025 · Filed Feb 3, 2026

MLAB$136.91+7.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

M****esa Laboratories, Inc.**

Condensed Consolidated Statements of Cash Flows

(in thousands)

Nine Months Ended December 31,
20252024
Cash flows from operating activities:
Net income$10,848$5,140
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment3,9894,028
Amortization of intangible assets13,53213,002
Stock-based compensation expense11,07510,004
Gain on extinguishment of convertible notes-(2,887)
Amortization of step-up in inventory basis-1,232
Foreign currency adjustments(5,800)2,492
Other4,1403,914
Cash from changes in operating assets and liabilities:
Accounts receivable, net92191
Inventories(3,460)(539)
Prepaid expenses and other assets(1,538)484
Accounts payable(873)(1,919)
Accrued liabilities and taxes payable(3,451)(50)
Unearned revenues(514)(849)
Net cash provided by operating activities28,86934,143
Cash flows from investing activities:
Purchases of property, plant and equipment(2,833)(3,492)
Net cash (used in) investing activities(2,833)(3,492)
Cash flows from financing activities:
Proceeds from debt borrowings107,50073,465
Repurchase and settlement of convertible note debt(97,500)(71,560)
Other debt principal repayments(22,062)(26,313)
GKE acquisition-related holdback payment(9,555)-
Dividends paid(2,639)(2,598)
Other financing, net(1,839)(1,310)
Net cash (used in) financing activities(26,095)(28,316)
Effect of exchange rate changes on cash and cash equivalents1,713407
Net increase in cash and cash equivalents1,6542,742
Cash and cash equivalents at beginning of period27,32128,214
Cash and cash equivalents at end of period$28,975$30,956
Supplemental non-cash activity:
Right of use assets obtained in exchange for lease liabilities$517$9,596

See accompanying notes to Condensed Consolidated Financial Statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.